# US 2024/0101975 A1 · Antibody Conjugates and Methods of Making and Using the Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0101975 A1
- Document ID: US20240101975A1
- Status: Published application
- Kind: A1
- Application number: 18/243,482
- Filed: 2023-09-07
- Published: 2024-03-28
- Earliest claimed: 2016-04-26
- Applicants: R.P. Scherer Technologies, LLC
- Inventors: Yun Cheol Kim; Chao Bai Huang; David Rabuka
- Web page: https://patentgrep.com/patent/US20240101975A1

## CPC

- C12N 9/0051: {acting on a sulfur group of donors (1.8)}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/30: from tumour cells
- C12Y 108/99: with other acceptors (1.8.99)
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Antibodies that include a sulfatase motif-containing tag in a constant region of an immunoglobulin (Ig) light chain polypeptide are disclosed. The sulfatase motif can be converted by a formylglycine-generating enzyme (FGE) to produce a formylglycine (fGly)-modified Ig light chain polypeptide. An fGly-modified Ig light chain polypeptide of the antibody can be covalently and site-specifically bound to a moiety of interest to provide an antibody conjugate. The disclosure also encompasses methods of production of such tagged Ig light chain polypeptides, fGly-modified Ig light chain polypeptides, and antibody conjugates, as well as methods of use of same.

## Claims

### Claim at position 1

-41. (canceled)

### Claim 42

An immunoglobulin (Ig) kappa light chain polypeptide comprising, in a constant region, an amino acid sequence selected from:
i) SEQ ID NO: 6, SEQ ID NO: 16, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 40, and SEQ ID NO: 42; or
ii) a sequence having, exclusive of the sequence LCTPSR (SEQ ID NO: 158), at least 90% sequence identity to a sequence from entry (i);
wherein the cysteine residue in the sequence LCTPSR (SEQ ID NO: 158) is oxidized to fGly.

### Claim 43 (depends on 42)

The Ig kappa light chain polypeptide of claim 42, wherein the fGly is covalently bound to a payload.

### Claim 44 (depends on 43)

The Ig kappa light chain polypeptide of claim 43, wherein the fGly is covalently bound to the payload via a hydrazone, oxime, semicarbazone, alkyl, alkenyl, acyloxy, hydrazinyl-indolyl, hydrazinyl-imidazoyl, hydrazinyl-pyrrolyl, hydrazinyl-furanyl or a pyrazolinone linkage.

### Claim 45 (depends on 43)

The Ig kappa light chain polypeptide of claim 43, wherein the fGly is covalently bound to the payload via a linking group.

### Claim 46 (depends on 45)

The Ig kappa light chain polypeptide of claim 45, wherein the linking group comprises a 4-aminopiperidine derivative (4AP).

### Claim 47 (depends on 43)

The Ig kappa light chain polypeptide of claim 43, wherein the payload is a drug, a detectable label, a water-soluble polymer, a viral fusion inhibitor, or a synthetic peptide.

### Claim 48 (depends on 47)

The Ig kappa light chain polypeptide of claim 47, wherein the drug is a small molecule drug.

### Claim 49 (depends on 48)

The Ig kappa light chain polypeptide of claim 48, wherein the small molecule drug is a cancer chemotherapeutic agent.

### Claim 50 (depends on 49)

The Ig kappa light chain polypeptide of claim 49, wherein the cancer chemotherapeutic agent is an alkylating agent, a nitrosourea, an antimetabolite, an antitumor antibiotic, a vinca alkaloid, or a steroid hormone.

### Claim 51 (depends on 47)

The Ig kappa light chain polypeptide of claim 47, wherein the water-soluble polymer is poly(ethylene glycol).

### Claim 52 (depends on 47)

The Ig kappa light chain polypeptide of claim 47, wherein the detectable label is an imaging agent.

### Claim 53 (depends on 42)

A recombinant nucleic acid comprising a nucleotide sequence encoding the Ig kappa light chain polypeptide of claim 42.

### Claim 54 (depends on 53)

A recombinant expression vector comprising the nucleic acid of claim 53, wherein the nucleotide sequence encoding the Ig kappa light chain polypeptide is operably linked to a promoter.

### Claim 55 (depends on 42)

A host cell genetically modified to express the Ig kappa light chain polypeptide of claim 42.

### Claim 56 (depends on 55)

The host cell of claim 55, genetically modified to express a formylglycine generating enzyme (FGE), in a manner sufficient to convert the Ig kappa light chain polypeptide into an fGly-modified Ig kappa light chain polypeptide.

### Claim 57 (depends on 56)

The host cell of claim 56, wherein the host cell is a mammalian cell.

### Claim 58 (depends on 42)

An antibody comprising the Ig kappa light chain polypeptide of claim 42.

### Claim 59 (depends on 58)

The antibody of claim 58, wherein the antibody specifically binds a tumor antigen on a cancer cell.

### Claim 60 (depends on 59)

A formulation comprising: the antibody of claim 59 and a pharmaceutically acceptable excipient.

### Claim 61

An immunoglobulin (Ig) kappa light chain polypeptide comprising, in a constant region, an amino acid sequence selected from the group consisting of: i) SEQ ID NO: 6, SEQ ID NO: 16, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 40, and SEQ ID NO: 42,
wherein the cysteine residue in the sequence LCTPSR (SEQ ID NO: 158) is oxidized to fGly.
